Literature DB >> 25634684

Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.

A Ray1, D S Das1, Y Song1, P Richardson1, N C Munshi1, D Chauhan1, K C Anderson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25634684      PMCID： PMC5703039          DOI： 10.1038/leu.2015.11

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  New checkpoint inhibitors ride the immunotherapy tsunami.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

2.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

3.  Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.

Authors:  H Tamura; M Ishibashi; T Yamashita; S Tanosaki; N Okuyama; A Kondo; H Hyodo; E Shinya; H Takahashi; H Dong; K Tamada; L Chen; K Dan; K Ogata
Journal:  Leukemia       Date:  2012-07-25       Impact factor: 11.528

Review 4.  Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

Authors:  D Atanackovic; T Luetkens; N Kröger
Journal:  Leukemia       Date:  2013-10-23       Impact factor: 11.528

5.  Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.

Authors:  William H D Hallett; Weiqing Jing; William R Drobyski; Bryon D Johnson
Journal:  Biol Blood Marrow Transplant       Date:  2011-04-12       Impact factor: 5.742

6.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

Authors:  Don M Benson; Courtney E Bakan; Anjali Mishra; Craig C Hofmeister; Yvonne Efebera; Brian Becknell; Robert A Baiocchi; Jianying Zhang; Jianhua Yu; Megan K Smith; Carli N Greenfield; Pierluigi Porcu; Steven M Devine; Rinat Rotem-Yehudar; Gerard Lozanski; John C Byrd; Michael A Caligiuri
Journal:  Blood       Date:  2010-05-11       Impact factor: 22.113

7.  Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

Authors:  Jacalyn Rosenblatt; Irit Avivi; Baldev Vasir; Lynne Uhl; Nikhil C Munshi; Tami Katz; Bimalangshu R Dey; Poorvi Somaiya; Heidi Mills; Federico Campigotto; Edie Weller; Robin Joyce; James D Levine; Dimitrios Tzachanis; Paul Richardson; Jacob Laubach; Noopur Raje; Vassiliki Boussiotis; Yan Emily Yuan; Lina Bisharat; Viki Held; Jacob Rowe; Kenneth Anderson; Donald Kufe; David Avigan
Journal:  Clin Cancer Res       Date:  2013-05-17       Impact factor: 12.531

8.  A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.

Authors:  A Ray; Z Tian; D S Das; R L Coffman; P Richardson; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2014-01-30       Impact factor: 11.528

9.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Authors:  Manish J Butte; Mary E Keir; Theresa B Phamduy; Arlene H Sharpe; Gordon J Freeman
Journal:  Immunity       Date:  2007-07-12       Impact factor: 31.745

10.  Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

Authors:  Dharminder Chauhan; Ajita V Singh; Mohan Brahmandam; Ruben Carrasco; Madhavi Bandi; Teru Hideshima; Giada Bianchi; Klaus Podar; Yu-Tzu Tai; Constantine Mitsiades; Noopur Raje; David L Jaye; Shaji K Kumar; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743
View more
  89 in total

Review 1.  Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

Authors:  Miguel-Angel Perales; Craig S Sauter; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-17       Impact factor: 5.742

2.  CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value.

Authors:  A Pardanani; K K Reichard; D Zblewski; R A Abdelrahman; E A Wassie; W G Morice Ii; C Brooks; K L Grogg; C A Hanson; A Tefferi; D Chen
Journal:  Leukemia       Date:  2015-12-18       Impact factor: 11.528

3.  Progress and Paradigms in Multiple Myeloma.

Authors:  Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

4.  The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.

Authors:  H Suen; R Brown; S Yang; P J Ho; J Gibson; D Joshua
Journal:  Leukemia       Date:  2015-05-19       Impact factor: 11.528

5.  Promising therapies in multiple myeloma.

Authors:  Giada Bianchi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

6.  Excess of the NF-ĸB p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1- and chemokines-mediated mechanisms.

Authors:  Yelena Kravtsova-Ivantsiv; Gilad Goldhirsh; Alexandra Ivantsiv; Ofer Ben Itzhak; Yong Tae Kwon; Eli Pikarsky; Aaron Ciechanover
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-09       Impact factor: 11.205

7.  Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Authors:  Gang An; Chirag Acharya; Xiaoyan Feng; Kenneth Wen; Mike Zhong; Li Zhang; Nikhil C Munshi; Lugui Qiu; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

8.  Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.

Authors:  Arghya Ray; Yan Song; Ting Du; Dharminder Chauhan; Kenneth C Anderson
Journal:  Oncogene       Date:  2020-02-05       Impact factor: 9.867

9.  Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.

Authors:  Dharminder Chauhan; Kenneth C Anderson; Ting Du; Yan Song; Arghya Ray
Journal:  Leukemia       Date:  2020-05-18       Impact factor: 11.528

10.  Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand in vitro.

Authors:  Zilong Hu; Yue Ma; Zhiyang Shang; Shidong Hu; Kai Liang; Wentao Liang; Xiaowei Xing; Yufeng Wang; Xiaohui Du
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.